- Home
- EYPT vs PEB Comparison
EYPT vs PEB Comparison
Compare EYPT & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | PEB |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2005 | 2009 |
Fundamental Metrics
Financial Performance| Metric | EYPT | PEB |
|---|---|---|
| Price | $15.19 | $11.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 10 |
| Target Price | ★ $28.75 | $12.35 |
| AVG Volume (30 Days) | 907.6K | ★ 2.1M |
| Earning Date | 03-04-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $42,339,000.00 | ★ $1,464,126,000.00 |
| Revenue This Year | N/A | $2.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.99 |
| 52 Week Low | $3.91 | $7.42 |
| 52 Week High | $19.11 | $14.21 |
Technical Indicators
Market Signals| Indicator | EYPT | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 41.94 |
| Support Level | $14.62 | $11.81 |
| Resistance Level | $16.73 | $12.79 |
| Average True Range (ATR) | 1.03 | 0.45 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 21.30 | 2.43 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.